[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Editor's Correspondence
December 11/25, 2000

Reduction of Buffalo Hump by Switching to Amprenavir in an HIV-Infected Patient

Arch Intern Med. 2000;160(22):3495-3496. doi:

Certain human immunodeficiency virus (HIV)–infected patients, within 6 to 18 months of the initiation of antiretroviral therapy, develop fat redistribution abnormalities consisting of body peripheral fat wasting with central fat deposition.1,2 Treatment of these morphological abnormalities remains a difficult challenge for case management. However, there are few clinical data to support the ability of amprenavir (Agenerase) to cause less lipodystrophy. We describe a patient whose buffalo hump was reduced by changing his regimen from indinavir sulfate (Crixivan) to amprenavir.

First Page Preview View Large
First page PDF preview
First page PDF preview
×